Orexigen Says Will Halt Obesity Drug Development as FDA Demands are Unreasonable

by Kathy Jones on  June 4, 2011 at 5:50 PM Corporate News
RSS Email Print This Page Comment
Font : A-A+

California based pharmaceutical company Orexigen Therapeutics has announced that it will be stopping the development of its diet pill in the American market citing "unprecedented" demands by the health regulators over the pill's safety.
 Orexigen Says Will Halt Obesity Drug Development as FDA Demands are Unreasonable
Orexigen Says Will Halt Obesity Drug Development as FDA Demands are Unreasonable

The company said that it will now be concentrating on getting the approval for its diet pill, known as Contrave and another drug candidate, Empatic, in other international markets.

The US Food and Drug Administration had refused to approve the drug back in February after concerns were raised that it could affect the heart.

Orexigen said that the FDA wanted it to conduct a large study looking into whether the drug actually affected the heart and the company said that the study would have unveiled information that was not necessary for its approval.

Source: Medindia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Bariatric Surgery Drug Toxicity Obesity Diabetes - Essentials Binge Eating : The Pleasure and Pain Bulimia Nervosa Body Mass Index Signature Drug Toxicity Liposuction Battle of the Bulge 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive